New Offering Integrates DOPPL’s Patient-Derived Intestinal Organoid Technology with InSphero’s Proven Standardized Screening Model

Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026 Timeline for submission of NDA dossier of deucrictibant IR for on-demand treatment of HAE attacks remains on-track in 1H2026 Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH atta

Lausanne, Switzerland — Leman Biotech Co., Ltd. announced encouraging clinical progress for META 10-19, its proprietary metabolically armored CD19-targeted CAR-T therapy. The first patient with mantle cell lymphoma (MCL) treated without lymphodepleting preconditioning achieved complete remission (CR).

Anaveon, a late-stage preclinical biotech focused on reprogramming the immune system with precision biologics, announces today the appointment of Thaminda Ramanayake as its new Chief Executive Officer.

Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of bradykinin B2 receptor antagonism in management of HAE

Amphasys, a leader in real-time, single‑cell analysis technologies, and Arsenale Bioyards, a neo‑industrial biomanufacturing company pioneering a fully integrated biomanufacturing platform, today announced the signing of a Joint Development Agreement (JDA) to combine their respective technologies into a next‑generation platform for the development and operation of advanced bioprocesses.